Hypophosphatemia Clinical Presentation

  • Author: Eleanor Lederer, MD; Chief Editor: Vecihi Batuman, MD, FACP, FASN   more...
 
Updated: Feb 13, 2012
 

History

Most patients with hypophosphatemia are asymptomatic. History alone rarely alerts the physician to the possibility of hypophosphatemia. In cases of oncogenic osteomalacia or in some of the genetic causes of phosphate wasting, patients complain of bone pain and fractures. Otherwise, physicians must have a high index of suspicion and must be aware of the clinical conditions that might be complicated by hypophosphatemia.[14]

Symptoms of hypophosphatemia are nonspecific and highly dependent on cause, duration, and severity.

  • Mild hypophosphatemia (ie, 2-2.5 mg/dL), whether acute or chronic, is generally asymptomatic. Occasionally, patients may complain of weakness, but whether the weakness is secondary to hypophosphatemia or is due to the underlying disorder causing the hypophosphatemia is not clear.
  • Acute mild hypophosphatemia commonly occurs with the treatment of diabetic ketoacidosis because of the sudden large doses of insulin used to treat the uncontrolled diabetes. However, mild hypophosphatemia is asymptomatic and rapidly reversed.
    • Mild hypophosphatemia can also occur after renal transplantation and can last years without any discernible symptoms.
    • Primary hyperparathyroidism is also associated with mild hypophosphatemia; however, the symptoms of hypercalcemia appear to be more prominent than those of mild hypophosphatemia.
  • Patients with severe and/or chronic hypophosphatemia are more likely to be symptomatic.
    • Moderate degrees of hypophosphatemia are commonly observed in patients with the refeeding syndromes. Most commonly, these individuals have a history of long-standing alcohol use and chronic malnutrition, resulting in the development of total body phosphate depletion.
    • When these patients are admitted to the hospital, their serum phosphate level is most often within the reference range. However, feeding stimulates insulin release, leading to a shift of phosphate from the extracellular to the intracellular compartment.
    • At times, the ensuing hypophosphatemia can be profound. Depending on the severity of the hypophosphatemia, the patient may complain of muscle weakness and generalized weakness or may develop the full-blown hypophosphatemic syndrome. In this particular clinical situation, if the practitioner does not have a high index of suspicion, the delirious state can be misinterpreted as delirium tremens.
    • The acute hypophosphatemic syndrome occurs most commonly in persons with chronic alcoholism, but it can also be observed in refeeding of patients who have eating disorders, patients who have been starved for any reason, or patients who are receiving parenteral nutrition with inadequate quantities of phosphate replacement.
  • Patients with chronic phosphate wasting syndromes frequently present with bone pain, muscle weakness, and skeletal disorders. In the genetic syndromes of renal phosphate wasting or acquired oncogenic osteomalacia, the serum phosphate level is generally moderately depressed. Symptoms are predominantly muscle weakness and bone pain or fractures.[15]
  • In short, symptoms alone rarely alert the physician to the possibility of hypophosphatemia. Recognizing that hypophosphatemia can complicate specific clinical conditions allows the physician to make this diagnosis.
    • Weakness, bone pain, rhabdomyolysis, and altered mental status are the most common presenting features of persons with symptomatic hypophosphatemia.
    • If considering the diagnosis of hypophosphatemia, the physician should attempt to elicit the following clinical clues to conditions associated with hypophosphatemia:
      • Poor nutrition
      • Symptoms of malabsorption
      • Excessive antacid use
      • Bone pain or fractures
      • Symptoms suggestive of multiple myeloma or other paraproteinemia
      • Treatment with parenteral nutrition
      • Exposure to heavy metals
      • Use of drugs such as glucocorticoids, cisplatin, or pamidronate
      • Treatment of diabetic ketoacidosis
      • Extensive burns
      • Use of growth factors
      • Bone marrow transplant
      • Intensive care unit (ICU) setting
Next

Physical

No physical signs are specific for hypophosphatemia. In fact, physical signs of mild hypophosphatemia are generally absent.

  • Chronic hypophosphatemia can be associated with short stature and evidence of rickets, with bowing of the legs, when caused by one of the genetically transmitted phosphate wasting disorders. In adults, chronic hypophosphatemia is more commonly associated with bone pain upon palpation.
  • Severe acute hypophosphatemia can have a variety of signs, including disorientation, seizures, focal neurologic findings, evidence of heart failure, and muscle pain.
  • Myocardial contractility may be impaired with ATP depletion, and respiratory failure due to weakness of the diaphragm has been described. The reduction in cardiac output may become clinically significant, leading to congestive heart failure, when the plasma phosphate concentration falls to 1.0 mg/dL (0.32 mmol/L).[16] Acute hypophosphatemia superimposed upon preexisting severe phosphate depletion can lead to rhabdomyolysis. Although CPK elevations are fairly common in hypophosphatemia, clinically significant rhabdomyolysis has been described almost exclusively in alcoholics and in patients receiving hyperalimentation without phosphate supplementation.
Previous
Next

Causes

The differential diagnosis of hypophosphatemia is most easily considered according to pathogenetic mechanisms. The following discussion conforms to this approach, but note that hypophosphatemia is frequently the result of more than one mechanism.

  • Inadequate intake
    • Hypophosphatemia due to inadequate intake is uncommon but should be strongly considered in certain patient populations. Inadequate ingestion can result from phosphate deficiency in the diet or from poor intestinal absorption. Patients who have had prolonged poor intake of phosphate develop true phosphate deficiency.
    • Persons with alcoholism who ingest an inadequate diet comprise one population at risk for this clinical scenario. Serum phosphate levels may be within reference ranges upon admission to the hospital, but refeeding stimulates cellular uptake and results in profound hypophosphatemia.
    • Similarly, critically ill patients receiving a parenteral diet deficient in phosphate may suddenly become hypophosphatemic as their catabolic condition resolves and they become more anabolic.
    • People with eating disorders or dietary deficiencies due to socioeconomic, dental, or swallowing difficulties may also become hypophosphatemic when fed an adequate diet.
    • Malabsorption of intestinal phosphate can be severe enough to produce phosphate deficiency and hypophosphatemia.
    • Individuals who ingest large quantities of antacids can become hypophosphatemic because of phosphate binding by the antacids, resulting in poor intestinal absorption.
    • Primary intestinal disorders, such as Crohn disease or celiac sprue, can limit phosphate absorption, leading to hypophosphatemia.
    • Similarly, steatorrhea or chronic diarrhea can cause mild-to-moderate hypophosphatemia due to decreased phosphate absorption from the gut and renal phosphate wasting; the latter is caused by secondary hyperparathyroidism induced by concomitant vitamin D deficiency.
    • Vitamin D deficiency causes hypophosphatemia by limiting intestinal and renal phosphate absorption.
  • Excessive losses
    • Phosphate wasting can result from genetic or acquired renal disorders. The genetic disorders generally manifest in infancy, when the children exhibit short stature and bone deformities.
      • X-linked hypophosphatemic rickets is characterized by short stature, radiographic evidence of rickets, and bone pain. Patients with this condition also may have calcification of tendons, cranial abnormalities, and spinal stenosis. In addition to hypophosphatemia, these patients have relatively low levels of 1,25 dihydroxyvitamin D-3, levels that are inappropriately low for the degree of hypophosphatemia. The defective gene is PHEX, which encodes for a membrane-bound neutral endopeptidase. Present understanding of this disorder is that the inactive neutral endopeptidase is unable to cleave a circulating phosphaturic substance. Data suggest that this circulating substance might be FGF23. This results in impaired phosphate reabsorption by decreasing the sodium-phosphate cotransporter in the kidneys.
      • Autosomal dominant hypophosphatemic rickets has similar manifestations, with hypophosphatemia, clinical rickets, and inappropriately low levels of 1,25 dihydroxyvitamin D-3. The cause of this disorder is thought to be mutations of FGF23 that result in resistance to degradation, persistently high circulating levels of FGF23, and subsequent phosphaturia.
      • Hereditary hypophosphatemic rickets with hypercalciuria is a rare disorder characterized by hypophosphatemia, phosphate wasting, hypercalciuria, bone pain, muscle weakness, and high levels of 1,25 dihydroxyvitamin D-3. The cause of this disorder is an inactivating mutation in the type 2c sodium-phosphate cotransporter.
      • Vitamin D–resistant rickets is an autosomal recessive disorder. In type I, the defect is in renal 1-alpha-hydroxylation. Type II is characterized by end organ resistance to the effects of 1,25 dihydroxyvitamin D-3. These patients present in childhood with hypocalcemia, hypophosphatemia, hyperparathyroidism, rickets, bone pain, muscle weakness, and alopecia. The disease is caused by mutations in the vitamin D receptor that prevent normal responsiveness to circulating vitamin D-3.
      • Mutations in the type 2a sodium-phosphate cotransporter have been reported in some patients with hypophosphatemia and inappropriate urinary phosphate wasting associated with nephrolithiasis and/or osteoporosis.[1, 17]
      • Rarely, significant renal phosphate wasting is observed in patients with fibrous dysplasia/McCune-Albright syndrome, disorders that result from mutations in the alpha subunit of the stimulatory G protein. Excess production of FGF23 has been found in some of these patients.[18]
    • Acquired phosphate wasting syndromes are of diverse etiologies.
      • Simple vitamin D deficiency results in hypophosphatemia, at least in part, from renal wasting. Vitamin D deficiency can result from several mechanisms, including poor oral intake, lack of sun exposure, drug-induced hypermetabolism of vitamin D precursors in the liver, or loss of vitamin D binding protein in the urine in persons with nephrotic syndrome. The loss of normal bone mineralization produces rickets in children and osteomalacia in adults.
      • Primary hyperparathyroidism is another cause of renal phosphate wasting.
      • Heavy metal intoxication and paraproteinemias can cause global proximal renal tubule dysfunction. These patients have hypophosphatemia along with type II renal tubular acidosis, renal glycosuria, aminoaciduria, and hypouricemia, ie, the condition referred to as Fanconi syndrome. Serum calcitriol concentrations can be either low or inappropriately normal. In children, cystinosis, Wilson disease, and hereditary fructose intolerance are the most common of the syndrome.
      • Drugs that can produce renal phosphate wasting include loop diuretics; acetazolamide; bisphosphonates, including pamidronate and zoledronate; and multiple chemotherapeutic and biologic agents, including cisplatinum; bevacizumab plus irinotecan[19] ; everolimus plus octreotide LAR[20] ; imatinib mesylate, a drug used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors[21, 22] ; sorafenib[23] ; carmustine[24] ; and ifosfamide.[25] In some circumstances, renal phosphate wasting is part of a more generalized, drug-induced Fanconi syndrome.[26]
      • Extracellular volume expansion or the administration of bicarbonate can cause loss of phosphate through the kidneys.
      • Oncogenic osteomalacia is a paraneoplastic syndrome characterized by osteomalacia, hypophosphatemia, renal phosphate wasting, bone pain, and muscle weakness. Several tumors that cause this syndrome have been described, most of which are benign tumors of mesenchymal origin.
      • Other factors that can increase urinary phosphate excretion are osmotic diuresis (most often due to glucosuria), proximally acting diuretics (acetazolamide and some thiazide diuretics that also have carbonic anhydrase inhibitory activity, such as metolazone), and acute volume expansion (which diminishes proximal sodium reabsorption).
  • Intracellular shift of phosphate
    • Several physiologic agents stimulate phosphate uptake from the extracellular environment into the cell. This phenomenon can exacerbate the hypophosphatemia caused by the previously described mechanisms and can result in profound hypophosphatemia. However, in some circumstances, the shift alone may be enough to produce hypophosphatemia, albeit of a milder degree.
    • Acute respiratory alkalosis or hyperventilation produces hypophosphatemia by stimulating a shift of phosphate into the cells. This mechanism is responsible for the hypophosphatemia observed with salicylate overdose, panic attacks, and sepsis. Extreme hyperventilation in normal subjects can lower serum phosphate concentrations to below 1.0 mg/dL (0.32 mmol/L), and it is probably the most common cause of marked hypophosphatemia in hospitalized patients. Less pronounced hypophosphatemia may occur during the increase in ventilation after the successful treatment of severe asthma. The effects of respiratory alkalosis are exacerbated by concomitant glucose infusions and may persist after hyperventilation ceases. Respiratory alkalosis also may be the precipitating factor in the hypophosphatemia-induced acute rhabdomyolysis that can occur in alcoholic patients.[27]
    • Insulin increases cell phosphate uptake and causes hypophosphatemia during treatment of diabetic ketoacidosis, refeeding, and parenteral nutrition therapy.
    • Exogenous epinephrine also stimulates cellular phosphate uptake.
    • Several cytokines reportedly stimulate intracellular phosphate shifts. This mechanism is perhaps responsible for the hypophosphatemia observed in the ICU setting of trauma, extensive burns, and bone marrow transplantation.
    • In hungry bone syndrome, rapid uptake of phosphate into bone occurs after the initial treatment of osteomalacia or rickets or postparathyroidectomy.
    • Hypophosphatemia is a common complication of kidney transplantation. Tertiary hyperparathyroidism has long been thought to be the etiology, but hypophosphatemia can occur despite low PTH levels and can persist after high PTH levels normalize. Furthermore, even in the setting of normal allograft function, hypophosphatemia, and hyperparathyroidism, calcitriol levels remain inappropriately low following transplantation, suggesting that mechanisms other than PTH contribute to phosphate homeostasis.
    • FGF23 induces phosphaturia, inhibits calcitriol synthesis, and accumulates in chronic kidney disease. This factor has been suggested as a possible mediator of posttransplantation hypophosphatemia. Dipyridamole enhances renal tubular phosphate reabsorption and has been shown to be effective in posttransplant hypophosphatemia in small studies.
Previous
Proceed to Differential Diagnoses
 
 
Contributor Information and Disclosures
Author

Eleanor Lederer, MD  Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital

Eleanor Lederer, MD is a member of the following medical societies: American Association for the Advancement of Science, American Federation for Medical Research, American Society for Biochemistry and Molecular Biology, American Society for Bone and Mineral Research, American Society of Nephrology, American Society of Transplantation, International Society of Nephrology, Kentucky Medical Association, National Kidney Foundation, and Phi Beta Kappa

Disclosure: Dept of Veterans Affairs Grant/research funds Research

Coauthor(s)

Rosemary Ouseph, MD  Professor of Medicine, Director of Kidney Transplant, University of Louisville School of Medicine

Rosemary Ouseph, MD is a member of the following medical societies: American Society for Bone and Mineral Research, American Society of Nephrology, and American Society of Transplant Surgeons

Disclosure: Nothing to disclose.

Snehal Patel, MD  Fellow, Department of Nephrology, University of Louisville School of Medicine

Snehal Patel, MD is a member of the following medical societies: American College of Physicians, American Society of Nephrology, Kentucky Medical Association, and Renal Physicians Association

Disclosure: Nothing to disclose.

Specialty Editor Board

James W Lohr, MD  Professor, Department of Internal Medicine, Division of Nephrology, Fellowship Program Director, University of Buffalo State University of New York School of Medicine and Biomedical Sciences

James W Lohr, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Nephrology, and Central Society for Clinical Research

Disclosure: Alexion Salary Employment

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Christie P Thomas, MBBS, FRCP, FASN, FAHA  Professor, Department of Internal Medicine, Division of Nephrology, Medical Director, Kidney and Kidney/Pancreas Transplant Program, University of Iowa Hospitals and Clinics

Christie P Thomas, MBBS, FRCP, FASN, FAHA is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Nephrology, and Royal College of Physicians

Disclosure: Nothing to disclose.

Rebecca J Schmidt, DO, FACP, FASN  Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine

Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association

Disclosure: Renal Ventures Ownership interest Other

Chief Editor

Vecihi Batuman, MD, FACP, FASN  Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Medicine Service, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, and International Society of Nephrology

Disclosure: Nothing to disclose.

Additional Contributors

We wish to thank Deepak Mittal, MD, and Datinder Deo, MD, for their previous contributions to this article.

References

  1. Lapointe JY, Tessier J, Paquette Y, Wallendorff B, Coady MJ, Pichette V. NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int. Jun 2006;69(12):2261-7. [Medline].

  2. Prié D, Huart V, Bakouh N, Planelles G, Dellis O, Gérard B, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med. 2002;347:983-991. [Medline].

  3. Jones A, Tzenova J, Frappier D, et al. Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the Na/Pi cotransporter NPT2 gene. J Am Soc Nephrol. Mar 2001;12(3):507-14. [Medline].

  4. Segawa H, Onitsuka A, Kuwahata M, Hanabusa E, Furutani J, Kaneko I, et al. Type IIc sodium-dependent phosphate transporter regulates calcium metabolism. J Am Soc Nephrol. 2009;20:104-113. [Medline].

  5. Nowik M, Picard N, Stange G, Capuano P, Tenenhouse HS, Biber J, et al. Renal phosphaturia during metabolic acidosis revisited: molecular mechanisms for decreased renal phosphate reabsorption. Pflugers Arch. 2008;457:539-549. [Medline].

  6. Collins JF, Bal L, Ghishan FK. The SLC20 family of protiens: dual functions as sodium-phosphate cotransporters and viral receptors. Pflugers Arch. 2004;447:647-652. [Medline].

  7. Virkki LV, Biber J, Murer H, Forster IC. Phosphate transporters: a tale of two solute carrier families. Am J Physiol Renal Physiol. 2007;293:F643-654. [Medline].

  8. Shaikh A, Berndt T, Kumar R. Regulation of phosphate homeostasis by the phosphatonins and other novel mediators. Pediatr Nephrol. Aug 2008;23(8):1203-10. [Medline].

  9. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. Jul 2006;291(1):E38-49. [Medline].

  10. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate?. Bone. Nov 2004;35(5):1192-9. [Medline].

  11. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?. Am J Physiol Renal Physiol. 2009;296:F70-476. [Medline].

  12. Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006;104(1):p23-32. [Medline].

  13. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. Dec 2006;70(12):2141-7. [Medline].

  14. Assadi F. Hypophosphatemia: an evidence-based problem-solving approach to clinical cases. Iran J Kidney Dis. Jul 2010;4(3):195-201. [Medline].

  15. Schubert L, DeLuca HF. Hypophosphatemia is responsible for skeletal muscle weakness of vitamin D deficiency. Arch Biochem Biophys. Aug 15 2010;500(2):157-61. [Medline].

  16. O'Connor LR, Wheeler WS, Bethune JE. Effect of hypophosphatemia on myocardial performance in man. N Engl J Med. Oct 27 1977;297(17):901-3. [Medline].

  17. Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf). Oct 1995;43(4):479-90. [Medline].

  18. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. Sep 2003;112(5):683-92. [Medline].

  19. Kreisl TN, Kimn L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent Bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurent glioblastoma. J Clin Oncol. 2009;27:740-745. [Medline].

  20. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Effricacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311-4318. [Medline].

  21. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. May 11 2006;354(19):2006-13. [Medline].

  22. Joensuu H, Reichardt P. Imatinib and altered bone and mineral metabolism. N Engl J Med. Aug 10 2006;355(6):628; author reply 628-9. [Medline].

  23. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients wtih metastatic renal cell cancer. J Clin Oncol. 2007;25:3288-3295. [Medline].

  24. Micetich KC, Futscher B, Koch D, Fisher RI, Erickson LC. Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. J Natl Cancer Inst. 1992;84:256-260. [Medline].

  25. Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer. 2007;48:447-452. [Medline].

  26. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24:19-38. [Medline].

  27. Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphataemia after voluntary hyperventilation. Clin Sci (Lond). May 2000;98(5):619-25. [Medline].

  28. Ambuhl PM, Meier D, Wolf B, et al. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis. Nov 1999;34(5):875-83. [Medline].

  29. Aubier M, Murciano D, Lecocguic Y, et al. Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure. N Engl J Med. Aug 15 1985;313(7):420-4. [Medline].

  30. Barak V, Schwartz A, Kalickman I, et al. Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines. Am J Med. Jan 1998;104(1):40-7. [Medline].

  31. Basquerizo A, Anselmo D, Shackleton C, et al. Phosphorus as an early predictive factor in patients with acute liver failure. Transplantation. 75:2007-2014. [Medline].

  32. Betro MG, Pain RW. Hypophosphataemia and hyperphosphataemia in a hospital population. Br Med J. Jan 29 1972;1(795):273-6. [Medline].

  33. Bollaert PE, Levy B, Nace L, et al. Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock. Chest. Jun 1995;107(6):1698-701. [Medline].

  34. Bowe AE, Finnegan R, Jan de Beur SM, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun. Jun 22 2001;284(4):977-81. [Medline].

  35. Camp MA, Allon M. Severe hypophosphatemia in hospitalized patients. Miner Electrolyte Metab. 1990;16(6):365-8. [Medline].

  36. Chung PY, Sitrin MD, Te HS. Serum phosphorus levels predict clinical outcome in fulminant hepatic failure. Liver Transplantation. 2003;9:248-253. [Medline].

  37. Cohen J, Kogan A, Sahar G, et al. Hypophosphatemia following open heart surgery: incidence and consequences. Eur J Cardiothorac Surg. 26:306-310. [Medline].

  38. Craddock PR, Yawata Y, VanSanten L, et al. Acquired phagocyte dysfunction. A complication of the hypophosphatemia of parenteral hyperalimentation. N Engl J Med. Jun 20 1974;290(25):1403-7. [Medline].

  39. Crook M. Hypophosphataemia in a hospital population and the incidence of concomitant hypokalaemia. Ann Clin Biochem. Jan 1992;29 ( Pt 1):64-6. [Medline].

  40. Crook MA, Hally V, Panteli JV. The importance of the refeeding syndrome. Nutrition. Jul-Aug 2001;17(7-8):632-7. [Medline].

  41. Daily WH, Tonnesen AS, Allen SJ. Hypophosphatemia--incidence, etiology, and prevention in the trauma patient. Crit Care Med. Nov 1990;18(11):1210-4. [Medline].

  42. DeFronzo RA, Lang R. Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin. N Engl J Med. Nov 27 1980;303(22):1259-63. [Medline].

  43. Dickerson RN, Gervasio JM, Sherman JJ, et al. A comparison of renal phosphorus regulation in thermally injured and multiple trauma patients receiving specialized nutrition support. JPEN J Parenter Enteral Nutr. May-Jun 2001;25(3):152-9. [Medline].

  44. DiMeglio LA, Econs MJ. Hypophosphatemic rickets. Rev Endocr Metab Disord. Apr 2001;2(2):165-73. [Medline].

  45. DiMeglio LA, White KE, Econs MJ. Disorders of phosphate metabolism. Endocrinol Metab Clin North Am. Sep 2000;29(3):591-609. [Medline].

  46. Drezner MK. PHEX gene and hypophosphatemia. Kidney Int. Jan 2000;57(1):9-18. [Medline].

  47. Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord. 2001;2:175-86. [Medline].

  48. Duerksen DR, Papineau N. Electrolyte abnormalities in patients with chronic renal failure receiving parenteral nutrition. JPEN J Parenter Enteral Nutr. Mar-Apr 1998;22(2):102-4. [Medline].

  49. Econs MJ. New insights into the pathogenesis of inherited phosphate wasting disorders. Bone. Jul 1999;25(1):131-5. [Medline].

  50. Faintuch J, Soriano FG, Ladeira JP, et al. Refeeding procedures after 43 days of total fasting. Nutrition. Feb 2001;17(2):100-4. [Medline].

  51. Gannage MH, Abikaram G, Nasr F, Awada H. Osteomalacia secondary to celiac disease, primary hyperparathyroidism, and Graves' disease. Am J Med Sci. Feb 1998;315(2):136-9. [Medline].

  52. Green J, Debby H, Lederer E, et al. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int. Sep 2001;60(3):1182-96. [Medline].

  53. Guy JM, Stewart MF, Olukoga A, et al. Hypophosphataemia in general practice patients. Ann Clin Biochem. Jan 1999;36 ( Pt 1):37-42. [Medline].

  54. Haglin L. Hypophosphataemia in anorexia nervosa. Postgrad Med J. May 2001;77(907):305-11. [Medline].

  55. Haglin L, Burman LA, Nilsson M. High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study. J Intern Med. Jul 1999;246(1):45-52. [Medline].

  56. Hardy DC, Murphy WA, Siegel BA, et al. X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology. May 1989;171(2):403-14. [Medline].

  57. Hicks W, Hardy G. Phosphate supplementation for hypophosphataemia and parenteral nutrition. Curr Opin Clin Nutr Metab Care. May 2001;4(3):227-33. [Medline].

  58. Jaureguiberry G, Carpenter TO, Forman S, Jüppner H, Bergwitz C. A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol. 2008;295:F371-379. [Medline].

  59. Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis. Feb 1992;19(2):99-120. [Medline].

  60. Kagansky N, Levy S, Koren-Morag N. Hypophosphataemia in old patients is associated with the refeeding syndrome and reduced survival. J Intern Med. 2005;257:461-468. [Medline].

  61. Kalaitzidis R, Tsimihodimos V, Bairaktari E, et al. Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis. 45:851-8. [Medline].

  62. Khardori R. Refeeding syndrome and hypophosphatemia. J Intensive Care Med. 2005;20:174-5. [Medline].

  63. Kohn MR, Golden NH, Shenker IR. Cardiac arrest and delirium: presentations of the refeeding syndrome in severely malnourished adolescents with anorexia nervosa. J Adolesc Health. Mar 1998;22(3):239-43. [Medline].

  64. Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm. 62:1663-82. [Medline].

  65. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone. Sep 2000;27(3):333-8. [Medline].

  66. Laaban JP, Grateau G, Psychoyos I, et al. Hypophosphatemia induced by mechanical ventilation in patients with chronic obstructive pulmonary disease. Crit Care Med. Nov 1989;17(11):1115-20. [Medline].

  67. Laaban JP, Waked M, Laromiguiere M, et al. Hypophosphatemia complicating management of acute severe asthma. Ann Intern Med. Jan 1 1990;112(1):68-9. [Medline].

  68. Lacy MQ, Gertz MA. Acquired Fanconi's syndrome associated with monoclonal gammopathies. Hematol Oncol Clin North Am. Dec 1999;13(6):1273-80. [Medline].

  69. Larsson L, Rebel K, Sorbo B. Severe hypophosphatemia--a hospital survey. Acta Med Scand. 1983;214(3):221-3. [Medline].

  70. Lee JH, Choi SJ, Lee JH, et al. Severe metabolic abnormalities after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 35:63-69. [Medline].

  71. Levi M. Novel NaPi-2c mutations that cause mistargeting of NaPi-2c protien and uncoupling of Na-Pi cause HHRH. Am J Physiol Renal Physiol. 2008;295:F369-370. [Medline].

  72. Lichtman MA, Miller DR, Cohen J, Waterhouse C. Reduced red cell glycolysis, 2, 3-diphosphoglycerate and adenosine triphosphate concentration, and increased hemoglobin-oxygen affinity caused by hypophosphatemia. Ann Intern Med. Apr 1971;74(4):562-8. [Medline].

  73. Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail. 2006;28(8):701-7. [Medline].

  74. Machiels JP, Dive A, Donckier J, Installe E. Reversible myocardial dysfunction in a patient with alcoholic ketoacidosis: a role for hypophosphatemia. Am J Emerg Med. Jul 1998;16(4):371-3. [Medline].

  75. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25- dihydroxyvitamin D-resistant rickets. Endocr Rev. Apr 1999;20(2):156-88. [Medline].

  76. Marinella MA. Refeeding syndrome and hypophosphatemia. J Intensive Care Med. 2005;20:155-159. [Medline].

  77. Marshall MR, Golper TA, Shaver MJ, et al. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int. 60:777-785. [Medline].

  78. Melvin JD, Watts RG. Severe hypophosphatemia: a rare cause of intravascular hemolysis. Am J Hematol. Mar 2002;69(3):223-4. [Medline].

  79. Milionis HJ, Alexandrides GE, Liberopoulos E, et al. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail. Mar 2002;4(2):167-73. [Medline].

  80. Miller DW, Slovis CM. Hypophosphatemia in the emergency department therapeutics. Am J Emerg Med. Jul 2000;18(4):457-61. [Medline].

  81. Morris AA, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS. Jan 5 2001;15(1):140-1. [Medline].

  82. Newman JH, Neff TA, Ziporin P. Acute respiratory failure associated with hypophosphatemia. N Engl J Med. May 12 1977;296(19):1101-3. [Medline].

  83. Ornstein RM, Golden NH, Jacobson MS, Shenker IR. Hypophosphatemia during nutritional rehabilitation in anorexia nervosa: implications for refeeding and monitoring. J Adolesc Health. 32:83-88. [Medline].

  84. Peacock M, Bilezekian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 90:135-141. [Medline].

  85. Perreault MM, Ostrop NJ, Tierney MG, et al. Efficacy and safety of intravenous phosphate replacement in critically ill patients. Ann Pharmacother. 31(6):683-8. [Medline].

  86. Polderman KH, Bloemers FW, Peerdeman SM, Girbes AR. Hypomagnesemia and hypophosphatemia at admission in patients with severe head injury. Crit Care Med. Jun 2000;28(6):2022-5. [Medline].

  87. Pomposelli JJ, Pomfret EA, Burns DL, et al. Life-threatening hypophosphatemia after right hepatic lobectomy for live donor adult liver transplantation. Liver Transpl. Jul 2001;7(7):637-42. [Medline].

  88. Prie D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens. Jul 2005;14(4):318-24. [Medline].

  89. Prie D, Blanchet FB, Essig M, et al. Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold. J Am Soc Nephrol. Jul 1998;9(7):1264-9. [Medline].

  90. Quarles LD, Drezner MK. Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab. Feb 2001;86(2):494-6. [Medline].

  91. Raanani P, Levi I, Holzman F, et al. Engraftment-associated hypophosphatemia -- the role of cytokine release and steep leukocyte rise post stem cell transplantation. Bone Marrow Transplantation. 2001;27:311-317. [Medline].

  92. Reid IR, Hardy DC, Murphy WA, et al. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore). Nov 1989;68(6):336-52. [Medline].

  93. Rubin MF, Narins RG. Hypophosphatemia: pathophysiological and practical aspects of its therapy. Semin Nephrol. Nov 1990;10(6):536-45. [Medline].

  94. Sankaran RT, Mattana J, Pollack S, et al. Laboratory abnormalities in patients with bacterial pneumonia. Chest. Mar 1997;111(3):595-600. [Medline].

  95. Schmitt CP, Mehls O. The enigma of hyperparathyroidism in hypophosphatemic rickets. Pediatr Nephrol. 2004;19:473-477. [Medline].

  96. Seifi S, Pezeshki ML, Khatami MR, et al. Post-renal transplantation hypophosphatemia. Transplant Proc. 35:2645-6. [Medline].

  97. Seikaly MG, Baum M. Thiazide diuretics arrest the progression of nephrocalcinosis in children with X-linked hypophosphatemia. Pediatrics. Jul 2001;108(1):E6. [Medline].

  98. Siddiqui MF, Bertorini TE. Hypophosphatemia-induced neuropathy: clinical and electrophysiologic findings. Muscle Nerve. May 1998;21(5):650-2. [Medline].

  99. Smyrniotis V, Kostopanagiotou G, Katsarelias D, et al. Changes of serum phosphorus levels in hepatic resections and implications on patients' outcomes. Int Surg. 88:100-4. [Medline].

  100. Steiner M, Steiner B, Wilhelm S, et al. Severe hypophosphatemia during hematopoietic reconstitution after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. May 2000;25(9):1015-6. [Medline].

  101. Strewler GJ. FGF23, hypophosphatemia, and rickets: has phosphatonin been found?. Proc Natl Acad Sci U S A. May 22 2001;98(11):5945-6. [Medline].

  102. Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore). Jan 2000;79(1):1-8. [Medline].

  103. Tan HP, Madeb R, Kovach SJ, et al. Hypophosphatemia after 95 right-lobe living-donor hepatectomies for liver transplantation is not a significant source of morbidity. Transplantation. 76:1085-8. [Medline].

  104. Vanneste J, Hage J. Acute severe hypophosphataemia mimicking Wernicke's encephalopathy. Lancet. Jan 4 1986;1(8471):44. [Medline].

  105. Vaszar LT, Culpepper-Morgan JA, Winter SM. Refeeding syndrome induced by cautious enteral alimentation of a moderately malnourished patient. Gastroenterologist. Mar 1998;6(1):79-81. [Medline].

  106. Vered Z, Battler A, Motro M, et al. Left ventricular function in patients with chronic hypophosphatemia. Am Heart J. Apr 1984;107(4):796-8. [Medline].

  107. Weintraub ME. Hypophosphatemis mimicking acute Guillanin-Barre-Strohl syndrome. A complication of parenteral hyperalimentation. JAMA. Mar 8 1976;235(10):1040-1. [Medline].

  108. Weintraub MI, Chakravorty HP. Nutrient deficiencies after intensive parenteral alimentation. N Engl J Med. 1974;291:799.

  109. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet. Aug 1 1998;352(9125):391-6. [Medline].

  110. Wilson HK, Keuer SP, Lea AS, et al. Phosphate therapy in diabetic ketoacidosis. Arch Intern Med. Mar 1982;142(3):517-20. [Medline].

  111. Yeung SJ, McCutcheon IE, Schultz P, Gagel RF. Use of long-term intravenous phosphate infusion in the palliative treatment of tumor-induced osteomalacia. J Clin Endocrinol Metab. Feb 2000;85(2):549-55. [Medline].

  112. Yu X, White KE. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev. 2005;16:221-232. [Medline].

  113. Zazzo JF, Troche G, Ruel P, Maintenant J. High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function. Intensive Care Med. Oct 1995;21(10):826-31. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.